Complete Guide to FDA New Dietary Ingredient (NDI) Notification for Taiwan Supplement Exporters

The Dietary Supplement Health and Education Act of 1994 (DSHEA) requires manufacturers and distributors to submit a New Dietary Ingredient (NDI) notification to the FDA at least 75 days before marketing any dietary supplement containing a dietary ingredient that was not marketed in the United States before October 15, 1994. This requirement is codified under 21 CFR 190.6 and applies equally to domestic producers and foreign exporters, meaning Taiwan supplement brands must comply before shipping product to US distributors or Amazon FBA warehouses. The 1994 cutoff date is strict: if you cannot demonstrate that your ingredient was commercially available in the US dietary supplement market before that date, you must file an NDI notification. Failure to submit a required NDI notification renders the product adulterated under Section 402(f) of the Federal Food, Drug, and Cosmetic Act, exposing the manufacturer to FDA enforcement actions including import alerts, warning letters, and product seizures.

Determining whether your ingredient qualifies as an NDI can be surprisingly complex. The FDA considers an ingredient "new" not only if the chemical entity itself is novel, but also if a previously marketed ingredient is used in a significantly different form, such as a new extraction method, a synthetic version of a naturally occurring compound, or a nano-particle formulation. For example, if your Taiwan facility produces a turmeric extract using supercritical CO2 extraction that yields a curcumin concentration above 95 percent, the FDA may classify this as a distinct NDI even though turmeric itself was marketed before 1994. Similarly, fermented versions of traditional ingredients, novel botanical combinations, and ingredients produced through biotechnology processes typically require NDI notification.

There are limited exemptions to the NDI notification requirement. If the ingredient has been present in the food supply as an article used for food in a form in which the food has not been chemically altered, it may be exempt under Section 413(a)(1) of the FD&C Act. However, this exemption is narrow: the ingredient must have been used as a conventional food, not merely as a traditional medicine or folk remedy. Taiwan exporters often mistakenly assume that traditional Chinese medicine ingredients automatically qualify for this exemption, but the FDA evaluates food supply presence based on US market history, not historical use in Asian markets.

LNH31 Global recommends that Taiwan supplement brands conduct a thorough ingredient review at least six months before their planned US market entry. Engage a US regulatory consultant familiar with the FDA's NDI database, which contains over 1,100 notifications submitted since 1994 and is publicly searchable on the FDA website. Cross-reference your ingredient list against both the NDI database and the American Herbal Products Association's (AHPA) Old Dietary Ingredient list to establish pre-1994 marketing history. This preliminary assessment typically costs $3,000 to $8,000 and can save you from the far more expensive full notification process if your ingredients turn out to be grandfathered.

The NDI notification must be submitted to the FDA's Office of Dietary Supplement Programs (ODSP) at least 75 calendar days before introducing the product into interstate commerce. The notification is submitted electronically through the FDA's Submissions Portal or by mail to the Office of Dietary Supplement Programs at 5001 Campus Drive, College Park, Maryland 20740. The 75-day clock begins on the date the FDA receives the notification, not the date you mail it. Taiwan exporters should factor in potential delays: the FDA may place a notification on hold if it is incomplete, which resets the 75-day period once the deficiency is corrected.

The notification itself must contain specific elements outlined in 21 CFR 190.6. You must include the name and complete address of the manufacturer or distributor, the name of the new dietary ingredient, a description of the dietary supplement containing the NDI including the level of the NDI in the product and the conditions of use, the history of use or other evidence of safety establishing that the ingredient is reasonably expected to be safe, and the signature of a responsible person. The safety evidence section is by far the most substantive part of the notification and typically accounts for 80 to 90 percent of the total document length, which can range from 50 to over 500 pages depending on the novelty of the ingredient.

After receiving the notification, the FDA has 75 days to review it but is not required to issue a formal approval. Instead, the FDA will either file the notification without objection, meaning you can proceed to market, or issue a response letter identifying concerns. Common FDA responses include a letter stating that the notification does not provide adequate evidence of safety, a letter requesting additional information, or in some cases, no response at all. If 75 days pass without any FDA communication, the notifier may legally proceed to market the product, although this does not constitute FDA approval or endorsement. The FDA can still take enforcement action after the 75-day period if it later determines the ingredient is unsafe.

Taiwan exporters should prepare their NDI notification package with meticulous attention to formatting and completeness. The FDA rejects a significant percentage of notifications on procedural grounds alone, such as missing manufacturer addresses, incomplete ingredient descriptions, or inadequate identity specifications. Work with a US-based regulatory affairs firm that has a track record of successful NDI filings. Firms such as REJIMUS, Ingredient Identity, and NaturPro Scientific charge between $15,000 and $50,000 for notification preparation, depending on the complexity of the ingredient and the extent of existing safety data. This investment is modest compared to the cost of a rejected notification, which can delay your US market entry by six months or more.

The FDA accepts two primary categories of evidence to establish that an NDI is reasonably expected to be safe: history of use and scientific safety data including toxicology studies. History of use evidence demonstrates that the ingredient has been consumed by humans for a sufficient period without documented adverse effects. The FDA generally considers 25 years of widespread human consumption as a reasonable threshold for history of use evidence, though this is a guideline rather than a fixed rule. For Taiwan exporters, documenting the history of use for traditional ingredients can be challenging because the FDA primarily considers use in the form and at the dose specified in the NDI notification, not general historical consumption in different forms or at different concentrations.

When history of use evidence is insufficient or unavailable, the notifier must provide scientific safety data. This typically includes a full toxicology package consisting of acute toxicity studies, sub-chronic (90-day) toxicity studies, genotoxicity studies (Ames test, chromosomal aberration, and mouse micronucleus assays), and reproductive toxicity studies. A complete toxicology package conducted according to Good Laboratory Practice (GLP) standards costs between $50,000 and $200,000 depending on the ingredient and the number of studies required. The most expensive component is usually the sub-chronic toxicity study, which alone can cost $40,000 to $80,000 and takes approximately four to six months to complete.

The FDA has increasingly emphasized the importance of identity specification in NDI notifications. You must provide detailed chemical characterization of your ingredient, including specifications for purity, potency, contaminant limits, and analytical methods used for identification. For botanical ingredients, this means providing the full binomial Latin name, plant part used, extraction solvent, solvent-to-herb ratio, and a certificate of analysis showing marker compound content. For fermented or biotechnology-derived ingredients, you must describe the production organism, fermentation conditions, and downstream purification steps. The FDA has rejected notifications where the ingredient identity was too vague to evaluate safety, even when substantial toxicology data was provided.

LNH31 Global advises Taiwan supplement brands to start with a gap analysis of their existing safety data before committing to expensive toxicology studies. Many ingredients common in Taiwan supplements have published human clinical trials, epidemiological data, or toxicology studies in the peer-reviewed literature that can be cited in an NDI notification. Databases such as PubMed, the Natural Medicines Comprehensive Database, and the European Food Safety Authority (EFSA) opinions archive are valuable sources. A qualified toxicologist can review existing literature and determine what additional studies, if any, are needed. This gap analysis typically costs $5,000 to $10,000 and can reduce your total toxicology spend by 30 to 60 percent if usable published data exists.

The FDA also evaluates the proposed conditions of use when assessing safety. This includes the daily dose, the intended population (adults vs children), the duration of use, and any label warnings. Setting a conservative daily dose and targeting only healthy adults can simplify the safety evaluation. Conversely, proposing use by pregnant women, children, or individuals with chronic diseases raises the evidentiary bar substantially. Taiwan exporters should align their proposed conditions of use with the available safety data rather than making broad usage claims that would require additional supporting evidence.

The FDA's NDI notification acknowledgment letters reveal consistent patterns in rejection reasons. According to FDA data, approximately 70 to 75 percent of NDI notifications receive some form of objection from the agency. The most common rejection reason is inadequate safety evidence, which accounts for roughly 50 percent of all objections. The FDA frequently states that the notifier failed to establish a reasonable expectation of safety because the submitted evidence did not adequately address the specific form, dose, or conditions of use proposed in the notification. Taiwan exporters should ensure that every piece of safety evidence directly relates to the exact ingredient specification and dosage in their product, not to a different form or concentration of the same compound.

The second most common rejection reason is inadequate ingredient identity, accounting for about 20 percent of objections. The FDA expects a level of chemical characterization that goes well beyond what most Taiwan manufacturers provide in their internal quality specifications. For example, simply stating that your product contains "green tea extract" is insufficient. The FDA wants to know the specific Camellia sinensis cultivar, the extraction method, the solvent used, the ratio of catechins and caffeine, the limits for pesticide residues and heavy metals, and the validated analytical methods used for identity testing. Investing in a comprehensive ingredient specification document before filing the notification eliminates this common rejection pathway.

Procedural deficiencies account for another 15 to 20 percent of rejections. These include notifications that fail to identify the manufacturer's address, omit the specific dietary supplement product containing the NDI, lack a signature from a responsible individual, or fail to provide the notification in English. Some Taiwan companies submit NDI notifications with product labels or technical documents in Mandarin, which the FDA cannot review. All documents must be in English, and any foreign-language source documents must be accompanied by certified English translations. Additionally, the notification must be submitted by the manufacturer or distributor of the dietary supplement, not by a contract testing laboratory or ingredient supplier on behalf of an unnamed downstream customer.

To maximize the probability of a successful NDI notification, Taiwan exporters should follow a structured preparation timeline. Begin the process 12 to 18 months before your target market entry date. Spend the first three months on ingredient identification and history of use research. If toxicology studies are needed, allocate four to six months for study conduct and an additional two months for report generation. Allow one to two months for notification drafting and internal review, then submit with a 75-day buffer plus an additional 30-day contingency for potential FDA questions. This 12 to 18 month timeline may seem long, but it is realistic for ingredients requiring new toxicology data and prevents costly delays caused by incomplete filings.